Hyderabad's Raghav Life Sciences develops Favipiravir for Covid-19 patients

Firm says it has been in talks with at least eight buyers, including a few overseas companies, to supply the anti-retroviral drug

Hyderabad-based active pharmaceutical ingredients(APIs) company Raghava Life Sciences said it has been in talks with at least eight buyers, including a few overseas companies, to supply the antiretroviral Favipiravir, which is currently being tested for treatment of coronavirus in several countries including India.

The company began working on Favipiravir in March after China indicated that the drug can potentially treat the infection based on initial results, said Raghava Life Sciences director P Lohit Reddy. The company, which expects hige for the drug, is likely to sign its first contract with the supply of a sample volume next week.